Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts
Blood · 22.02.2024 · 143 (8) · 661-672
DOI: 10.1182/blood.2022018096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, erschienen am 22.02.2024. Verfasst von Angelo Nascimbene und 2 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Cardiopulmonary Therapies and Transplantation, University of Texas, Houston, TX. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart, Artificial, Heart Failure, Thrombosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Over the past 2 decades, there has been a significant increase in the utilization of long-term mechanical circulatory support (MCS) for the treatment of cardiac failure. Left ventricular assist devices (LVADs) and total artificial hearts (TAHs) have been developed in parallel to serve as bridge-to-transplant and destination therapy solutions. Despite the distinct hemodynamic characteristics introduced by LVADs and TAHs, a comparative evaluation of these devices regarding potential complications in supported patients, has not been undertaken. Such a study could provide valuable insights into the complications associated with these devices. Although MCS has shown substantial clinical benefits, significant complications related to hemocompatibility persist, including thrombosis, recurrent bleeding, and cerebrovascular accidents. This review focuses on the current understanding of hemostasis, specifically thrombotic and bleeding complications, and explores the influence of different shear stress regimens in long-term MCS. Furthermore, the role of endothelial cells in protecting against hemocompatibility-related complications of MCS is discussed. We also compared the diverse mechanisms contributing to the occurrence of hemocompatibility-related complications in currently used LVADs and TAHs. By applying the existing knowledge, we present, for the first time, a comprehensive comparison between long-term MCS options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Advanced Cardiopulmonary Therapies and Transplantation, University of Texas, Houston, TX.
- Division of Hematology and Oncology, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.
- Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO.
- Université de Paris-Cité, Innovative Therapies in Haemostasis, INSERM, Paris, France.
- Hematology Department, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital, Paris, France.
ORCID-Profile: David Bark, David M Smadja
Förderung
- NHLBI NIH HHS
- NIBIB NIH HHS
Zitieren
APA
Nascimbene, A., Bark, D., & Smadja, D. M. (2024). Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts. Blood, 143(8), 661-672. https://doi.org/10.1182/blood.2022018096
Vancouver
Nascimbene A, Bark D, Smadja DM. Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts. Blood. 2024;143(8):661-672. doi:10.1182/blood.2022018096
BibTeX
@article{Nascimbene2024,
author = {Nascimbene, Angelo and Bark, David and Smadja, David M},
title = {Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts},
journal = {Blood},
year = {2024},
volume = {143},
number = {8},
pages = {661--672},
doi = {10.1182/blood.2022018096}
}
EUVIMED